Connection

Naphak Modhiran to Spike Glycoprotein, Coronavirus

Back to Details
This is a "connection" page, showing publications Naphak Modhiran has written about Spike Glycoprotein, Coronavirus.
Naphak Modhiran
Connection Strength
0.058
Spike Glycoprotein, Coronavirus
  1. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021 10; 21(10):1383-1394.
    View in: PubMed
    Score: 0.026
  2. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody. Sci Rep. 2021 02 08; 11(1):3318.
    View in: PubMed
    Score: 0.026
  3. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021 04 01; 12(1):2037.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.